Forefront Collaborative | Improving Patient Outcomes in Rheumatoid Arthritis: Disease Activity Measurement to Optimize Treating to Target
If you could boil the purpose of CME down to just one thing, it would be to improve patient outcomes. Short, succinct, and to the point, our collaboration with the American College of Rheumatology (ACR) ultimately created a one-hour CME activity that focused on rheumatoid arthritis (RA) disease activity measurement, treating to target strategy, the pathophysiology of RA in relation to conventional and emerging therapies, and the American College of Rheumatology (ACR)’s Rheumatology Informatics System for Effectiveness (RISE) rapid-cycle registry reports, presented as a lively discussion between leaders in the field--Juliet Aizer, MD, MPH, Jinoos Yazdany, MD, MPH, Sheetal Desai, MD, MSEd, FACR , and Salahuddin Kazi, MD. Supported by an educational grant from Pfizer, the program also provided rheumatologists participating in ACR’s Rapid Cycle Performance Assessment Activity the ability to interact with these panelists in a real time Q&A proved as indispensible as it was enlightening—for both parties—when it comes to discovering new ways to optimize treatment. For those unable to attend live or by viewing the Webcast online or who wish for a refresher, the educational content resides [HERE] [https://acrlearningcenter.org/Activity/4250357/Detail.aspx#lnk4250357]
Rheumatology, Forefront, Rheumatoid, Arthritis, Juliet, Aizer, Jinoos, Yazdany, Sheetal, Desai, Salahuddin, Kazi, RA,
16888
post-template-default,single,single-post,postid-16888,single-format-standard,,qode-title-hidden,qode_grid_1200,footer_responsive_adv,qode-theme-ver-9.1.2,wpb-js-composer js-comp-ver-4.11.2,vc_responsive

12 Aug Improving Patient Outcomes in Rheumatoid Arthritis: Disease Activity Measurement to Optimize Treating to Target

 Rheumatoid Arthritis / Live Meeting at ACR’s Rapid Cycle Assessment Activity 

If you could boil the purpose of CME down to just one thing, it would be to improve patient outcomes. Short, succinct, and to the point, our collaboration with the American College of Rheumatology (ACR) ultimately created a one-hour CME activity that focused on rheumatoid arthritis (RA) disease activity measurement, treating to target strategy, the pathophysiology of RA in relation to conventional and emerging therapies, and the American College of Rheumatology (ACR)’s Rheumatology Informatics System for Effectiveness (RISE) rapid-cycle registry reports, presented as a lively discussion between leaders in the field–Juliet Aizer, MD, MPH, Jinoos Yazdany, MD, MPH; Sheetal Desai, MD, MSEd, FACR; and Salahuddin Kazi, MD. Supported by an educational grant from Pfizer, the program also provided rheumatologists participating in ACR’s Rapid Cycle Performance Assessment Activity the ability to interact with these panelists in a real-time Q&A, which proved as indispensable as it was enlightening—for both parties—when it comes to discovering new ways to optimize treatment.

For those unable to attend live or by viewing the Webcast online or who wish for a refresher, the educational content resides here.